Recent Company News

• 02:00 PM ET Sep 28, 2026
  

  StreetAccount Summary - Private Company Weekly Recap - Week of 21-Sep

• 11:11 AM ET Sep 10, 2026
  

  StreetAccount Summary - US unusual volume traders

• 09:53 AM ET Sep 21, 2026
  

  FDA grants orphan drug designation to nuzefatide pevedotin for the treatment of pancreatic cancer ($3.68, +0.03)

• 10:06 AM ET Sep 16, 2026
  

  StreetAccount Summary: Stocks reaching new 52-week highs/lows (137 total)

• 10:05 AM ET Aug 03, 2026
  

  StreetAccount Summary: Stocks reaching new 52-week highs/lows (162 total)

• 11:16 PM ET Jul 30, 2026
  

  Bicycle Therapeutics assumed outperform at Oppenheimer; prior rating was outperform ($4.01, 0.00)

• 10:35 AM ET Jul 30, 2026
  

  StreetAccount Summary: Stocks reaching new 52-week highs/lows (124 total)

• 07:07 AM ET Jul 30, 2026
  

  Bicycle Therapeutics reports Q2 EPS ($0.72) vs FactSet ($0.58) [9 est, ($0.75)-(0.37)] ($3.86, 0.00)

• 10:01 AM ET Jun 25, 2026
  

  StreetAccount Summary: Stocks reaching new 52-week highs/lows (324 total)